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In 2007, cervical cancer was the 13th most common site of cancer registration for New Zealand (NZ) females.1 Incidence and 
mortality rates are relatively low compared 
with the rest of the developed world,2 but are 
not the same across ethnic groups within NZ. 
For example, in 2005, Māori women had an 
incidence rate of 9.0, Pacific women 16.3 and 
‘Other’ (predominantly European) women 
5.6 per 100,000 women; Māori women 
had a mortality rate of 6.5, Pacific women 
7.1 and ‘Other’ women 1.4 per 100,000 
women.3 In 2007, the age-standardised 
mortality (standardised to the World Health 
Organization standard world population) rate 
was 2.2 per 100,000 women but again varied 
by ethnicity: 4.5 per 100,000 in Māori women 
compared with 2.0 in non-Māori women.1 
The difference in the mortality rate between 
Māori and non-Māori women has fluctuated 
over the past few years but appears to have 
decreased to an approximately two-fold 
difference (unpublished data from the NZ 
Ministry of Health provided to, and analysed 
by, the authors).
There are major demographic differences 
in cervical cancer screening4 in NZ, and 
the National Screening Unit therefore has 
an on-going campaign (see http://www.
nsu.govt.nz/current-nsu-programmes/2445.
aspx) to increase cervical screening rates 
particularly in Māori and Pacific women who 
are currently under screened.5 There are also 
major demographic differences in cervical 
cancer stage at diagnosis6 and mortality in 
NZ.6,7 In previous analyses adjustment for 
stage at diagnosis, socio-economic position 
(SEP), and urban/rural residence explained 
only some of the increased mortality risks 
in Māori and Pacific women (compared with 
‘Other’ women).6 Ethnic differences in stage 
at diagnosis were not entirely explained by 
differences in screening history.4 Adjustment 
for comorbid conditions accounted for a 
moderate proportion of the ethnic differences 
in mortality.8
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Key words: Uterine cervical neoplasms, 
ethnicity, geographical variation, 
inequalities, New Zealand
Aust NZ J Public Health. 2012; 36:335-42
doi: 10.1111/j.1753-6405.2012.00843.x
Travel time and distance to health care only partially 
account for the ethnic inequalities in cervical cancer 
stage at diagnosis and mortality in New Zealand
Naomi Brewer
Centre for Public Health Research, Massey University, New Zealand
Neil Pearce
Centre for Public Health Research, Massey University, New Zealand; and 
Department of Medical Statistics, Faculty of Epidemiology and Public Health, 
London School of Hygiene and Tropical Medicine, UK
Peter Day
GeoHealth Laboratory, Department of Geography, University of Canterbury,  
New Zealand
Barry Borman
Centre for Public Health Research, Massey University, New Zealand
Submitted: February 2011 Revision requested: July 2011 Accepted: November 2011
Correspondence to: Dr Naomi Brewer, Centre for Public Health Research,  
Massey University – Wellington Campus, PO Box 756, Wellington 6140, New Zealand;  
e-mail: N.Brewer@massey.ac.nz
Article Indigenous Health
336 AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH 2012 vol. 36 no. 4
© 2012 The Authors. ANZJPH © 2012 Public Health Association of Australia
Brewer et al. Article
Thus, the reasons for the ethnic differences in mortality are 
currently unclear, but one possibility not previously examined is 
that they may be due to differences in travel time and/or distance to 
the nearest general practitioner (GP) and/or cancer treatment centre. 
Travel time and distance could impact on mortality by affecting 
rates of screening and therefore stage at diagnosis or more directly 
by affecting access to, or utilisation of, treatment once women have 
been diagnosed. In NZ, McLeod et al.9 found that some healthcare 
providers perceived transportation, including the financial cost of 
travelling long distances to cancer centres, as well the required time, 
and the levels of tiredness that patients experience, to be a barrier 
to accessing treatment, resulting in some women not attending 
scheduled appointments or refusing treatment altogether.
Internationally, several studies have shown travel distance to, or 
remoteness from, GP practices and cancer treatment facilities, to 
have a negative impact on cancer mortality and survival.10-13 These 
effects may be mediated through later stage at diagnosis and lower 
utilisation of health services, possibly because of the higher financial 
costs and inconvenience.11 Lack of access to healthcare in rural 
areas, due to transportation problems or fewer primary healthcare 
providers and specialist diagnostic and treatment services has been 
associated with reduced cervical cancer screening and treatment.14,15 
Yabroff et al.16 suggest that rural physicians are less likely to offer 
cervical screening compared with their non-rural counterparts. 
Rural residence has also been shown to be associated with higher 
mortality rates.14,16 Travel time and distance, and the associated 
costs and inconvenience of transportation, have been shown to be a 
perceived barrier to care17 and may lead to “patients opting to forgo 
needed care”,18 especially in ethnic minorities. 
However, not all studies internationally19 or in NZ6,20-22 have 
found consistent associations between travel distance or remoteness 
and cancer stage, mortality and survival. Haynes et al.22 found 
no evidence of a later stage at diagnosis in those living furthest 
from either a cancer centre or a GP. They found poorer survival in 
prostate cancer patients who had longer travel times to a GP, and for 
patients with colorectal, breast or prostate cancer who had longer 
travel times to a cancer centre, but not for lung cancer or melanoma 
patients. Bennett et al.20 did not find an association between urban/
rural residence and breast cancer stage or survival. Gill and Martin21 
found an inconsistent association between distance from a cancer 
centre and upper gastrointestinal cancer, with those living 51-100 
kilometres (km) away having a worse prognosis than those living 
>200 km away. 
There are geographic and ethnic variations in GP accessibility 
in NZ. Māori live relatively more in rural areas and therefore have 
longer travel times to their nearest GP; Pacific people are more 
urban and have shorter travel times.23 However, there have been few 
studies of the effects on cancer survival in NZ.6,20-22 Furthermore, for 
cervical cancer (as with breast cancer) there is a national screening 
programme, and the possibility therefore exists to study screening 
history. We here investigate whether travel time and/or distance 
accounts for the previously observed ethnic differences in cervical 
cancer screening, stage at diagnosis and mortality.
Methods
The source population was all cervical cancer cases registered 
with the NZ Cancer Registry (NZCR) between 1 January 1994 and 
31 December 2005.4,6 The NZCR records self-identified ethnicity. 
Participants who reported more than one ethnicity were classified 
into a single ethnicity using the standard system of prioritisation: 
Māori > Pacific > Asian > ‘Other’.24 The latter category includes 
participants with missing ethnicity data. This approach is standard 
practice in NZ health research.25,26 All registrations include the 
unique National Health Index (NHI) number; this was used to obtain 
cause-specific mortality data (from the Mortality Collection) up 
to the end of December 2005 (the most recent year for which data 
was available), and to obtain the woman’s cervical screening history 
from the National Cervical Screening Programme (NCSP) Register.
The classifications of screening history were based on those 
used for the New Zealand Cervical Cancer audit27 and for quality 
monitoring by the NCSP.28 Women were categorised as ‘not 
screened’ or ‘ever screened’. We excluded smears taken in the six 
months immediately prior to diagnosis since some of these will 
have been taken for diagnostic, not screening, purposes.29,30 The 
full details of the categorisation have been described elsewhere.4 
Cervical screening guidelines are extremely complex,31 and the 
categories used in this study are only able to approximate the 
women’s screening histories.27
SEP was estimated using the New Zealand Deprivation Index 
2001 (NZDep), an area-based measure derived from the national 
census.32 Each participant was assigned a score based on the 
residential area (domicile code) in which they lived, as recorded 
at registration on the NZCR. These scores were then grouped into 
quintiles.32
Data on stage at diagnosis were obtained from the NZCR, and 
reported using the International Federation of Gynecology and 
Obstetrics (FIGO)33 system. In order to provide sufficient numbers 
in each category, the FIGO stages were grouped into four categories: 
stages 0-IB2; II-IIB; III-IIIB; IVA-IVB. The FIGO stages were also 
further grouped into early stage (FIGO stages 0-IB2) and late stage 
(FIGO stages II-IVB) for some analyses. Women with an unknown 
stage at diagnosis, or who could not be allocated a deprivation score, 
were excluded from the analyses. We conducted a sensitivity analysis 
to assess the potential for bias resulting from the exclusion of these 
women that showed that the study findings were generally similar 
whether these women were included or excluded; we have therefore 
excluded them because it is necessary to adjust for stage, and this 
is the only approach which enables us to do this validly.8 There was 
little ethnic or socioeconomic difference in the percentage of cases 
with missing FIGO codes.4
The methods used to estimate travel time and distance to the 
nearest GP and cancer centre were based on those of Haynes et al.22 
and Pearce et al.34 The domicile code recorded for each participant 
was matched to a 2001 Census Area Unit (CAU), allowing a location 
to be assigned to each participant. The travel time (in minutes, and 
proportions of minutes) and distance (in metres) to the nearest GP 
surgery (n=1,383) and to the nearest of the six cancer centres were 
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calculated from the population weighted centroids of each of the 
1,860 CAUs across NZ, using the road network functionality in a 
Geographical Information System.22 These were then categorised 
according to the method of Haynes et al:22 Low – the lowest quartile; 
Medium – quartiles two and three; High – records between the 
75 and 95 percentiles; Highest – the highest 5% of records. “The 
reason for dividing the fourth quartile into categories 3 and 4 was 
to distinguish the most extreme values of journey times ... where 
the greatest effect might be expected”.22
All analyses were conducted using Intercooled Stata 11.1 
for Windows (StataCorp, College Station, Texas, US). Logistic 
regression was used to estimate the associations with stage at 
diagnosis. Cox regression was used to estimate adjusted cervical 
cancer mortality hazard ratios (HRs). All analyses were adjusted 
for ethnicity, age, registration year and SEP. In general, the findings 
were similar for travel time and distance, but these were strongly 
correlated with each other, and were therefore not included in 
the models at the same time, because of potential problems of 
multicollinearity. 
The New Zealand Central Ethics Committee granted ethical 
approval for the study (CEN/08/04/EXP).
Results
There were 2,323 cases of cervical cancer registered on the NZCR 
between 1 January 1994 and 31 December 2005. The following 
exclusions were made: 17 women because their cancer registration 
was made on the date of the woman’s death, 126 because they did 
not have a domicile code that could be assigned an NZDep score 
or used to estimate their travel time and distance, 555 because 
they did not have a FIGO code, and a further 31 because they 
were diagnosed after 30 June 2005 (and therefore had a potential 
follow-up time of less than six months). This left 1,594 women 
to be included in the analyses. Of these: 99.2% were diagnosed 
based upon the histology of the primary malignant tumour;6 1,163 
(73%) identified as ‘Other’ ethnicity, 312 of whom died during the 
follow-up period, 241 (77%) due to cervical cancer, and 71 (23%) 
due to other causes; 292 identified as Māori ethnicity (18%), 104 
of whom died, 92 (88%) due to cervical cancer, and 12 (12%) due 
to other causes; 59 (4%) identified as Pacific ethnicity, 20 of whom 
died, 20 (100%) due to cervical cancer; and, 80 (5%) identified as 
Asian ethnicity, 14 of whom died, 13 (93%) due to cervical cancer, 
and one (7%) due to other causes.8
Table 1 shows the characteristics of the 1,594 cervical cancer 
Table 1: Characteristics of women diagnosed with cervical cancer in New Zealand, 1994 to 2005.
Characteristic Ethnicity
All womenMāori Pacific Asian Other
Women, n (%) 292 (18.3) 59 (3.7) 80 (5.0) 1163 (73.0) 1594
Travel time (median)
Time to nearest GP 1.66 1.98 1.82 1.70 1.71
Time to nearest cancer centre 45.12 17.83 14.39 23.6 22.26
Travel distance (median)
Distance to nearest GP 856.53 954.59 936.84 871.87 876.71
Distance to nearest cancer centre 50995.10 14382.42 12530.42 20742.58 20742.58
Travel time, categorised n (%)
Time to nearest GP
  Low (>0.00 – <0.98) 83 (28.4) 19 (32.2) 19 (23.8) 283 (24.3) 404 (25.4)
  Medium (≥0.98 – <2.96) 131 (44.9) 29 (49.2) 50 (62.5) 580 (49.9) 790 (49.6)
  High (≥2.96 – 11.07) 51 (17.5) 10 (17.0) 11 (13.8) 248 (21.3) 320 (20.1)
  Highest (≥11.07) 27 (9.3) 1 (1.7) 0 52 (4.5) 80 (5.0)
Time to nearest cancer centre
  Low (>0.00 – <12.38) 45 (15.4) 13 (22.0) 33 (41.3) 306 (26.3) 397 (24.9)
  Medium (≥12.38 – <94.29) 154 (52.7) 43 (72.9) 42 (52.5) 561 (48.2) 800 (50.2)
  High (≥94.29 – <268.56) 79 (27.1) 3 (5.1) 5 (6.3) 232 (20.0) 319 (20.0)
  Highest (≥268.56) 14 (4.8) 0 0 64 (5.5) 78 (4.9)
Travel distance, categorised n (%)
Distance to nearest GP
  Low (>0.00 – <523.39) 78 (26.7) 18 (30.5) 18 (22.5) 284 (24.4) 398 (25.0)
  Medium (≥523.39 – <1573.03) 132 (45.2) 30 (50.9) 52 (65.0) 583 (50.1) 797 (50.0)
  High (≥1573.03 – <9988.50) 57 (19.5) 10 (17.0) 10 (12.5) 241 (20.7) 318 (20.0)
  Highest (≥9988.50) 25 (8.6) 1 (1.7) 0 55 (4.7) 81 (5.1)
Distance to nearest cancer centre
  Low (>0.00 – <8290.68) 44 (15.1) 12 (20.3) 29 (36.3) 314 (27.0) 399 (25.0)
  Medium (≥8290.68 – <114780.00) 154 (52.7) 44 (74.6) 46 (57.5) 553 (47.6) 797 (50.0)
  High (≥114780.00 – <313865.20) 74 (25.3) 3 (5.1) 5 (6.3) 238 (20.5) 320 (20.1)
  Highest (≥313865.20) 20 (6.9) 0 0 58 (5.0) 78 (4.9)
Distance is in metres. Time is in minutes and proportions of minutes.
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cases included in the analyses. The percentage of women in the 
highest category of travel time to the nearest GP (more than 11.07 
minutes) varied by ethnicity (p=0.001) and ranged from 9.3% of 
Māori women to 0% of Asian women. No Pacific or Asian women 
lived in the highest category of travel time to the nearest cancer 
centre (more than 268.56 minutes) compared with 4.8% of Māori 
women and 5.5% of ‘Other’ women. Similar patterns were found 
for travel distance.
Both travel time and distance had little or no association with 
having ever been screened (Table 2), and adjustment for travel time 
or distance made almost no difference to the ethnic differences in 
screening rates. For example, the highest category of travel time 
to the nearest GP had an odds ratio (OR) of 0.99 (95% CI 0.57-
1.72) for having ever been screened, compared to never screened. 
Adjustment for travel time made little change to the OR for ‘ever 
screened’ for Māori (a change from 0.54 to 0.55) or Pacific women 
(a change from 0.28 to 0.30).
The analyses shown in Table 2 were repeated (not shown) using 
‘regular screening’ (see 4 for definition) as the outcome (all of those 
who were not regularly screened were classified as ‘not regularly 
screened’). The ethnic differences were generally less than those 
shown in Table 2, but the patterns of the (lack of) effect of adjusting 
for travel time/distance were the same. For example, the OR for 
regular screening in Māori (compared to ‘Other’) women was 
0.75 (95% CI 0.50-1.11) when adjusted for age, registration year 
and NZDep, and this changed to 0.76 (0.51-1.13) when adjusted 
Table 2: Screening history and stage at diagnosis by ethnicity, socioeconomic position, and travel time/distance.
Characteristic Odds ratios (95% CI) for ever screened vs never 
screened
Odds ratios (95% CI) for late stage diagnosis 
(stage II-IV) vs early stage diagnosis (0-IB2)
Adjusted for 
ethnicity, age, 
registration year 
and NZDep
Adjusted for 
ethnicity, age, 
registration 
year, NZDep 
and travel time
Adjusted for 
ethnicity, age, 
registration 
year, NZDep and 
travel distance
Adjusted for 
ethnicity, age, 
registration 
year and NZDep
Adjusted 
for age, 
registration 
year, NZDep 
and travel time
Adjusted 
for age, 
registration 
year, NZDep 
and travel 
distance
Ethnicity
Māori
Pacific
Asian
Other
0.54 (0.40-0.73)
0.28 (0.15-0.54)
0.42 (0.24-0.72)
1.00
0.55 (0.40-0.75)
0.30 (0.16-0.58)
0.42 (0.24-0.73)
1.00
0.55 (0.40-0.75)
0.30 (0.16-0.58)
0.43 (0.25-0.74)
1.00
2.71 (1.98-3.72)
1.39 (0.76-2.54)
1.07 (0.63-1.82)
1.00
 
2.59 (1.88-3.56)
1.26 (0.68-2.33)
1.04 (0.61-1.78)
1.00
2.64 (1.92-3.63)
1.26 (0.68-2.33)
1.04 (0.61-1.77)
1.00
NZDep, quintiles
1 (least deprived)
2
3
4
5 (most deprived)
1.00
1.04 (0.68-1.59)
1.04 (0.70-1.56)
0.85 (0.58-1.25)
1.20 (0.82-1.77)
1.00
1.02 (0.66-1.57)
0.96 (0.64-1.45)
0.79 (0.53-1.18)
1.10 (0.73-1.65)
1.00
1.02 (0.66-1.56)
0.99 (0.66-1.49)
0.81 (0.54-1.20)
1.12 (0.75-1.68)
1.00
0.90 (0.57-1.43)
1.24 (0.81-1.90)
1.26 (0.84-1.89)
1.09 (0.72-1.65)
1.00
0.95 (0.59-1.51)
1.29 (0.84-2.00)
1.34 (0.88-2.05)
1.21 (0.78-1.86)
1.00
0.95 (0.59-1.51)
1.31 (0.84-2.02)
1.35 (0.89-2.07)
1.20 (0.78-1.85)
Travel time/distance
Time to nearest GP
Low
Medium
High
Highest
1.00
1.22 (0.92-1.62)
1.00 (0.71-1.42)
0.99 (0.57-1.72)
1.00
1.26 (0.95-1.68)
1.02 (0.71-1.45)
0.91 (0.52-1.60)
–
–
–
–
1.00
1.28 (0.96-1.72)
1.17 (0.81-1.70)
1.67 (0.95-2.94)
1.00
1.27 (0.94-1.71)
1.12 (0.77-1.64)
1.70 (0.95-3.04)
–
–
–
–
Time to nearest cancer 
centre
Low
Medium
High
Highest
1.00
0.88 (0.66-1.16)
1.21 (0.86-1.70)
1.04 (0.60-1.81)
1.00
0.90 (0.68-1.21)
1.31 (0.91-1.87)
1.09 (0.62-1.91)
–
–
–
–
1.00
1.33 (0.99-1.79)
1.09 (0.75-1.57)
0.58 (0.30-1.13)
1.00
1.32 (0.97-1.79)
1.06 (0.72-1.56)
0.56 (0.29-1.10)
–
–
–
–
Distance to nearest GP
Low
Medium
High
Highest
1.00
1.08 (0.82-1.43)
1.01 (0.71-1.43)
0.92 (0.53-1.58)
–
–
–
–
1.00
1.11 (0.84-1.48)
1.01 (0.71-1.44)
0.83 (0.47-1.45)
1.00
1.12 (0.83-1.49)
1.18 (0.82-1.70)
1.37 (0.78-2.40)
–
–
–
–
1.00
1.10 (0.82-1.48)
1.14 (0.79-1.67)
1.48 (0.83-2.64)
Distance to nearest 
cancer centre
Low
Medium
High
Highest
1.00
0.88 (0.66-1.17)
1.32 (0.93-1.86)
0.91 (0.52-1.59)
–
–
–
–
1.00
0.90 (0.67-1.21)
1.39 (0.97-1.99)
0.96 (0.54-1.69)
1.00
1.29 (0.96-1.74)
0.99 (0.69-1.43)
0.77 (0.41-1.46)
–
–
–
–
1.00
1.26 (0.93-1.71)
0.94 (0.64-1.38)
0.72 (0.38-1.38)
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for travel time to the nearest GP and cancer centre, and to 0.76 
(0.51-1.13) when adjusted for travel distance to the nearest GP and 
cancer centre. There was a similar lack of change in the findings 
for Pacific and Asian women when adjusting for travel time and 
distance (not shown).
Travel time to the nearest GP was non-significantly associated 
with late stage diagnosis (OR = 1.67, 95% CI 0.95-2.94) (Table 2), 
whereas travel time to the nearest cancer centre had a non-significant 
negative association with late stage diagnosis (OR=0.58, 95% CI 
0.30-1.13). Adjustment for travel time reduced the excess risk of 
late-stage diagnosis by about 7% in Māori (the OR reduced from 
2.71 to 2.59) and 33% in Pacific women (the OR reduced from 
1.39 to 1.26). Similar findings were observed when adjusting for 
travel distance.
Travel time to the nearest GP and cancer centre were only weakly 
and inconsistently associated with cervical cancer-specific mortality 
(adjusted for stage) (Table 3); for example, the highest category of 
travel time to the nearest GP had a non-significant positive HR of 
1.32 (95% CI 0.79-2.19) for mortality, whereas there was little or no 
association with travel time to the nearest cancer centre. Adjustment 
for travel time reduced the excess risk of mortality by 3% in Māori 
(the HR reduced from 1.59 to 1.57) and 13% in Pacific women (the 
HR reduced from 1.92 to 1.80). Similar findings were observed 
when using travel distance rather than travel time.
Discussion
This study found that travel time/distance is only weakly 
associated with cervical cancer screening, stage at diagnosis and 
mortality in NZ. Adjustment for travel time reduced the excess risk 
of late-stage diagnosis by about 7% in Māori and 33% in Pacific 
women, and adjustment for travel time reduced the excess risk of 
mortality by about 3% in Māori and 13% in Pacific women. Thus, 
the relatively weak effects of travel time primarily affect the ethnic 
Table 3: Hazard ratios for mortality by ethnicity and travel time/distance.
Characteristic Number of 
deaths
HR (95% CI) adjusted 
for age, registration 
year, ethnicity, stage 
and NZDep
HR (95% CI) adjusted for 
age, registration year, 
ethnicity, stage, NZDep 
and travel time
HR (95% CI) adjusted for 
age, registration year, 
ethnicity, stage, NZDep and 
travel distance
Ethnicity
Māori
Pacific
Asian
Other
92
20
13
241
1.59 (1.21-2.08)
1.92 (1.20-3.08)
0.70 (0.40-1.22)
1.00
1.57 (1.19-2.06)
1.80 (1.11-2.91)
0.67 (0.38-1.18)
1.00
1.58 (1.20-2.07)
1.90 (1.17-3.07)
0.68 (0.39-1.21)
1.00
NZDep2001, quintiles
1 (least deprived)
2
3
4
5 (most deprived)
38
41
75
95
117
1.00
0.97 (0.62-1.51)
1.32 (0.89-1.96)
1.14 (0.78-1.66)
1.15 (0.78-1.70)
1.00
1.04 (0.66-1.63)
1.41 (0.94-2.11)
1.25 (0.84-1.86)
1.29 (0.86-1.94)
1.00
1.03 (0.65-1.62)
1.42 (0.95-2.14)
1.24 (0.83-1.85)
1.25 (0.83-1.88)
Travel time/distance
Time to nearest GP
Low
Medium
High
Highest
85
193
67
21
1.00
1.13 (0.87-1.47)
1.33 (0.95-1.86)
1.28 (0.78-2.10)
1.00
1.13 (0.87-1.47)
1.33 (0.94-1.87)
1.32 (0.79-2.19)
–
–
–
–
Time to nearest cancer centre
Low
Medium
High
Highest
81
201
71
13
1.00
1.12 (0.87-1.46)
1.03 (0.74-1.42)
1.02 (0.56-1.86)
1.00
1.08 (0.83-1.42)
0.96 (0.68-1.36)
0.96 (0.52-1.75)
–
–
–
–
Distance to nearest GP
Low
Medium
High
Highest
90
187
72
17
1.00
0.98 (0.76-1.27)
1.23 (0.89-1.70)
0.93 (0.55-1.58)
–
–
–
–
1.00
0.98 (0.75-1.26)
1.23 (0.88-1.71)
0.95 (0.55-1.64)
Distance to nearest cancer 
centre
Low
Medium
High
Highest
81
200
70
15
1.00
1.07 (0.82-1.40)
1.00 (0.72-1.38)
1.04 (0.59-1.84)
–
–
–
–
1.00
1.03 (0.79-1.35)
0.95 (0.67-1.34)
1.02 (0.57-1.81)
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differences in stage at diagnosis, rather than subsequent survival 
(at a given stage of diagnosis).
A strength of the study is that the Cancer Registry Act (effective 
from 1994) makes cancer registration mandatory,1 and case under-
ascertainment unlikely.25 Death registration is also mandatory in NZ, 
and can be linked to cancer registrations using the NHI number; 
thus there is a high probability that the study identified all of the 
cases that died in NZ. There may have been some misclassification 
of cause of death, but it is unlikely to have produced significant bias 
in the ethnic comparisons.35 Furthermore, classification of the cause 
of death for patients on the NZCR is highly accurate since in cases 
that are registered prior to death, information from the NZCR is 
used to classify the underlying cause of death.36
This is the first study in NZ to measure the associations between 
travel time or distance (measured from the population weighted 
centroid of the CAU of residence of cervical cancer patients to 
the nearest GP and cancer centre), and cervical cancer-specific 
mortality. The few previous NZ studies that have examined the 
association between distance and cervical cancer mortality have 
used less precise measures of distance, such as aggregate measures 
based on population size.6,8 Internationally, previous studies have 
also used less accurate methods of estimating distance/remoteness 
by using geometric centroids of census areas of residence (rather 
than population weighted centroids) and/or by estimating the 
travel time or distance to the centroids of census areas or to towns 
containing healthcare facilities (rather than to the specific location 
of a GP or cancer centre).12,13,37 This is also the first study in NZ to 
use more direct measures of travel time or distance to assess their 
associations with cervical screening history.
The limitations of the study include the potential misclassification 
of ethnicity, which has been estimated to produce a 17-23% 
undercount of Māori cancer registrations38,39 (this involves 
misclassification of ethnicity on registrations, rather than case under-
ascertainment). The estimated undercount varies by time period 
(from about 23% in the 1990s to 15% in 2001-04).39 Pacific and 
Asian cancer registrations are also estimated to be undercounted by 
18-10%, and 38-13%, respectively, from the 1990s to mid-2000s.39 
Thus, the ‘Other’ ethnic group may contain some Māori, Pacific 
and Asian cases that were incorrectly classified, thereby diluting the 
ethnic survival differences. However, any resulting bias is likely to 
be small; for example, if mortality is double in Māori compared to 
‘Other’ women, and 20% of Māori are misclassified as ‘Other’, this 
would only produce a bias in the HR of about 5% (i.e. if the true HR 
was 2.0, the observed HR would be 1.9). There is also evidence of a 
6–7% under-count of Māori deaths,38,40 but this would not bias the 
current study since the ethnicity recorded on the NZCR was used in 
all analyses. The classification of ethnicity was based on the wording 
of the corresponding census questions, and these have changed over 
time, but this is unlikely to have produced serious bias because 
the ethnicity recorded on the NZCR was also used to classify the 
corresponding deaths, and the analyses were adjusted for registration 
year. There may also be misclassification of area-based SEP, but any 
such misclassification is unlikely to be associated with subsequent 
survival and, if anything, is likely to produce under-estimates of the 
differences in survival between the various demographic groups. 
Only 74% of cases recorded on the NZCR between January 1994 
and June 2005 had a FIGO code,6 which could introduce selection 
bias, but a previous analysis found that there was little difference 
in overall cancer survival between those with and those without 
stage data.41 It is also possible that there was residual confounding 
from inaccuracies in stage classification, as there were not sufficient 
numbers to adjust for more detailed stage at diagnosis. Thus, 
residual confounding by stage could explain some of the results. 
However, the fact that in our previous analysis6 the Māori/‘Other’ 
differences in mortality almost completely disappeared when the 
analyses were adjusted for stage indicates that this is not likely to 
be a serious source of bias.
The estimates of travel time and distance are limited in their 
accuracy since we used domicile codes and were not able to 
estimate the time or distance from the patient’s residential address, 
and we were not able to estimate the time or distance to the actual 
GP surgery or cancer centre that the patient attended. Women may 
choose to travel to a more distant GP, but it is unlikely that they 
would choose to travel to a more distant cancer centre since there are 
only six in NZ. The women that choose to travel to a more distant 
GP are presumably more likely to live nearby to several GPs, such 
that the actual time or distance travelled is not greatly different to 
our estimations. Thus, there may be some misclassification of travel 
time and distance but it is likely to be small. Travel time and distance 
to healthcare facilities may be associated with a number of social 
and cultural factors, but it is likely that these are generally related 
to both ethnicity and SEP, which we adjusted for in our analyses.
The findings from previous studies of travel time and/or distance 
and cancer survival in NZ have been inconsistent. Gill and Martin21 
found that after adjusting for other variables, distance from a 
cancer centre was not associated with poorer survival from upper 
gastrointestinal cancers. However, the relationship was complex as 
they found in univariate analyses that those living 51-100 km from a 
cancer centre had a poorer prognosis, but this difference disappeared 
when adjusted for gender, age, ethnicity, and NZDep96, although 
these analyses were not adjusted for stage/extent of disease.21 Haynes 
et al.22 found that after adjusting for extent of disease, increasing 
travel time to the nearest GP was associated with poorer survival 
for men with prostate cancer. Travel to the nearest cancer centre was 
also independently associated with poorer survival for colorectal 
and breast cancer patients, and less consistently associated with an 
adverse outcome in prostate cancer patients.22 Half their sample 
lived within an estimated 2.1 minutes’ drive to the nearest GP and 
more than half the sample lived within an estimated one hour’s 
drive to the nearest cancer centre.22 In contrast, Bennett et al.20 
found that after adjustment for stage and other variables distance 
from a cancer centre did not affect survival of women with breast 
cancer. “Just under a third of the cohort [examined by Bennett et 
al.20] lived within 10 km of a cancer centre. Another third lived 11-
50 km away, 15% lived 51-100 km, and the remaining 22.3% lived 
more than 100 km away from a cancer centre.” We have previously 
Brewer et al. Article
2012 vol. 36 no. 4 AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH 341
© 2012 The Authors. ANZJPH © 2012 Public Health Association of Australia
shown that urban/rural residence had only a small effect on ethnic 
disparities in cervical cancer survival after adjusting for other 
variables including stage.6
Studies in other countries (such as Australia and the US, both 
substantially geographically larger than NZ) have also yielded 
inconsistent findings. In Australia, Aboriginal women in rural and 
remote areas were found to have a higher risk of death from cervical 
cancer than Aboriginal women living in urban areas.12 The opposite 
pattern was observed for non-Aboriginal women. This study did 
not adjust for stage at diagnosis or screening history.12 Jong et al.37 
were able to adjust for stage at diagnosis and found a significant 
increase in the relative excess risk of death for women with cervical 
cancer living in a remote area of New South Wales. In New York 
state, Tan et al.13 found that increasing driving time (from resident’s 
county seat to the nearest cancer treatment centre’s county seat) led 
to an increase in the cervical cancer-specific death rate even when 
adjusting for population density. However, they were not able to 
adjust for stage. The pattern varied over time: in 1979 rural counties 
had an excess of around 1.5 deaths per 100,000 women compared 
with more densely populated counties, but by 2001 the rural counties 
had lower rates than the urban counties by roughly one death per 
100,000 women.13 Coker et al.42 also found significantly shorter 
cervical cancer-specific survival in women living in more rural 
areas of Texas, after adjustment for stage (and treatment, age, race, 
SEP, and cell type). When stratified by stage, the association was 
only significant for women with regional/distant disease (compared 
with localised and unknown).42
The (weak) associations that we found between travel time and 
the ethnic differences in stage at diagnosis persisted after adjustment 
for screening history; similarly the ethnic differences in mortality 
persisted after adjustment for stage at diagnosis. Thus, there may 
be ethnic variations in access to treatment or in treatment quality, 
which in turn may be related to travel time.37 There is some evidence 
for variation in treatment quality43-45 and disease management46 
in NZ. However, the only study to date on treatment related to 
cervical cancer found that there were no differences in receipt of 
total/radical hysterectomy or brachytherapy between Māori and 
non-Māori after adjusting for age and stage of disease (excluding 
those with unknown stage).47 The study was not able to examine 
external beam radiotherapy or chemotherapy which are generally 
provided on an outpatient basis.47 A follow-up study that used focus 
groups to explore health service provider views on the finding of 
this study47 that “...there were substantial improvements in the 
disparities between Māori and non-Māori women in cervical cancer 
incidence, mortality and survival...”9 (between 1996 and 2006) 
found that the participants thought that one reason for the decrease 
in the inequalities might be a “trend towards improved consistency 
of practice [in terms of treatment] across the country...”.9
These initial analyses of inequalities in cervical cancer survival 
in NZ provide timely baseline data. NZ commenced a vaccination 
program with Gardasil (Merck, Auckland, NZ) in September 2008, 
which will provide vaccinated women with immunity to human 
papillomavirus (HPV) subtypes 16, 18, 6 and 11. However, subtypes 
16 and 18 are estimated to only account for about 70% of current 
cervical cancer cases (the exact figure is unknown because a national 
HPV prevalence survey has not been done), and the vaccine will 
not yield major benefits for several decades.
In summary, we assessed the associations of travel time and 
distance with cervical cancer screening, stage at diagnosis and 
mortality. We found that both travel time and distance are only 
weakly associated with these outcomes, but they may account for 
a small proportion of the ethnic differences in stage at diagnosis 
and mortality, particularly for Pacific women. These relatively weak 
effects of travel time primarily affect stage at diagnosis, rather than 
subsequent survival (at a given stage of diagnosis). It is possible 
that other factors, including differences in treatment and follow-up 
also play a role.
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